



RECEIVED

APR 01 2003

TECH CENTER 1600/2000

Attorney Docket No. 172.2USDC2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bischofberger et al.

Serial No.: 09/801,164

Group No.: 1653

Filed: March 7, 2001

Examiner: D. Lukton

For: Nucleotide Analogs

COPY

Assistant Commissioner for Patents

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT (modified)

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ FORM PTO - 1449 (Modified)
3. ☒ Identification of Prior Application in Which Listed Information Was Already Cited.

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

☒ 37 CFR 1.8 (a)
with sufficient postage as
first class mail

or

☐ 37 CFR 1.10
as "Express Mail Post
Office to Addressee" Mailing
Label
No. _____

Robin Torres

(Type or print name of person mailing paper)

Date: December 7, 2001

Robin Torres
(Signature of person mailing paper)



RECEIVED

APR 01 2003

TECH CENTER 1600/2900

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose. To the extent that this submission includes an International Search Report, such Report is submitted to facilitate the Examiner's analysis of the references and not out of any belief that the International Searching Authority's construction of the relevance of the references has any bearing under United States Law.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Section 3. Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

This application relies, under 35 U.S.C. 120, at least on the earlier filing dates of prior applications:

Serial No. 09/247,497	, filed on	February 10, 1999
Serial No. 09/071,420	, filed on	May 1, 1998
Serial No. 08/617,849	, filed on	May 6, 1996
Serial No. 08/193,341	, filed on	February 8, 1994
Serial No. 08/123,483	, filed on	September 17, 1993

Copies of references are not supplied to the extent that they are found in the file history of the prior application(s). Copies of references that were not supplied in the prior application(s), if any, accompany this paper.

Reg. No. 27,043

Tel. No.: (650) 522-5878

SIGNATURE OF ATTORNEY

Max D. Hensley

Type or print name of attorney

Gilead Sciences, Inc.

333 Lakeside Drive

P.O. Address

Foster City, CA 94404